ResMed (ResMed) ROCE % : 22.41% (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is ResMed ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ResMed's annualized ROCE % for the quarter that ended in Dec. 2023 was 22.41%.

ResMed ROCE % Historical Data

The historical data trend for ResMed's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ResMed ROCE % Chart

ResMed Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROCE %

Get a 7-Day Free Trial

18.18

21.47

23.39

24.37

22.15

ResMed Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															22.14	20.22	19.17	19.33	22.41

ResMed ROCE % Calculation

ResMed's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	1151.997	/	( ( (5095.853 - 689.299)	+	(6751.708 - 758.533) )	/ 2 )
	=	1151.997	/	( (4406.554	+	5993.175)	/ 2 )
	=	1151.997	/	5199.8645
	=	22.15 %

ResMed's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	1357.288	/	( ( (6740.786 - 770.802)	+	(6905.088 - 764.073) )	/ 2 )
	=	1357.288	/	( ( 5969.984	+	6141.015 )	/ 2 )
	=	1357.288	/	6055.4995
	=	22.41 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

ResMed (NYSE:RMD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ResMed ROCE % Related Terms

Thank you for viewing the detailed overview of ResMed's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

ResMed (ResMed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ResMed Inc (NYSE:RMD) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

RSMDF:USA RMEA:Germany RME:Germany RMEA:Germany RME:Germany R1MD34:Brazil RMD:Australia

Address

9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123

Website

https://www.resmed.com

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Executives

Brett Sandercock	officer: Chief Financial Officer	17 GUINEVIERE COURT, CASTLE HILL, NEW SOUTH WALES C3 2154
Michael J. Farrell	officer: Chief Executive Officer	C/O REMED INC, 9001 SPECTRUM CTR. BLVD., SAN DIEGO, CA 92123
Michael J Rider	officer: Global General Counsel	9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
Robert Andrew Douglas	officer: President and COO	21 ATTUNGA ROAD, NEWPORT, NEW SOUTH WALES C3 2106
Kaushik Ghoshal	officer: President, SaaS Business	9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
David Pendarvis	officer: Chief Administration Officer	REDMED INC, 14040 DANLELSON ST, POWAY CA 92064
Karen Drexler	director	C/O DIADEXUS, INC., 343 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Justin Leong	officer: President, Asia and LATAM	C/O RESMED INC, 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
Desney Tan	director	9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
John Hernandez	director	9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Lucile Blaise	officer: President, Sleep & RC Business	RESMED INC., 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Peter C Farrell	director	RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
James Hollingshead	officer: President, Sleep Business	C/O RESMED INC., 9001 SPECTRUM CENTER BOULEVARD, SAN DIEGO CA 92123
Carol Burt	director	C/O WELLCARE HEALTH PLANS, INC., 8725 HENDERSON ROAD, TAMPA FL 33634
Resmed Inc	director	9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123